PRESS RELEASE published on 02/17/2026 at 08:30, 1 month 9 days ago Inventiva reports preliminary 2025¹ fiscal year financial results Inventiva reports preliminary 2025 fiscal year financial results, showing €99.3 million in cash, €131.6 million in short-term deposits, and €4.5 million in revenues Revenues Financial Results Clinical-stage Inventiva Cash Equivalents
BRIEF published on 02/04/2026 at 22:05, 1 month 22 days ago Inventiva at the Guggenheim Biotech Summit 2026 New York Inventiva MASH Lanifibranor Biotech Summit
BRIEF published on 02/04/2026 at 22:05, 1 month 22 days ago Inventiva to Participate in Guggenheim Biotech Summit 2026 Biopharmaceuticals Inventiva MASH Lanifibranor Biotech Summit
PRESS RELEASE published on 02/04/2026 at 22:00, 1 month 22 days ago Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Inventiva to present at Guggenheim Emerging Outlook: Biotech Summit 2026. CEO Andrew Obenshain to participate in fireside chat on February 11, 2026, in New York City Fireside Chat Inventiva Biotech Summit Guggenheim Emerging Outlook CEO Andrew Obenshain
BRIEF published on 01/30/2026 at 11:21, 1 month 27 days ago JP Morgan Chase & Co.'s reduced stake in INVENTIVA Shares Threshold Crossing Right To Vote JP Morgan Inventiva
BRIEF published on 01/26/2026 at 22:05, 2 months ago Inventiva's Liquidity Contract with Kepler Cheuvreux: Half-Year Update Liquidity Contract Kepler Cheuvreux Biopharmaceutical Inventiva MASH
PRESS RELEASE published on 01/26/2026 at 22:00, 2 months ago Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Inventiva's half-year review of liquidity contract with Kepler Cheuvreux reveals cash & share details as of Dec 2025, showing increase from previous report Liquidity Contract Kepler Cheuvreux Financial Report Biopharmaceutical Inventiva
BRIEF published on 01/20/2026 at 15:57, 2 months 6 days ago JP Morgan crosses thresholds in INVENTIVA's capital Actions Stock Market Crossing Thresholds JP Morgan Inventiva
BRIEF published on 12/15/2025 at 11:22, 3 months 11 days ago Threshold crossings by JP Morgan at Inventiva Voting Rights Capital Crossing Thresholds JP Morgan Inventiva
BRIEF published on 11/28/2025 at 16:01, 3 months 28 days ago JP Morgan falls below the 5% threshold at Inventiva Voting Rights Actions Threshold Crossing JP Morgan Inventiva
Published on 03/26/2026 at 23:00, 6 hours 31 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 7 hours 26 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 7 hours 31 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 7 hours 31 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 8 hours 31 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/27/2026 at 05:15, 15 minutes ago Neapco Holdings LLC Announces the Official Close of IFA Group Acquisition, Creating a Global Leader in Driveline Solutions
Published on 03/27/2026 at 04:00, 1 hour 30 minutes ago Tech-Driven Restoration: Saving the World's Critically Endangered White-headed Langur
Published on 03/26/2026 at 20:48, 8 hours 42 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 10 hours 10 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 18:17, 11 hours 14 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 17:45, 11 hours 46 minutes ago Cegedim: profitability continues to improve
Published on 03/26/2026 at 07:30, 22 hours 1 minute ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
